Related Experiment Video

Updated: Aug 22, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

Modulation of the JNK pathway in liver affects insulin resistance status

Yoshihisa Nakatani1, Hideaki Kaneto, Dan Kawamori

  • 1Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.

The Journal of Biological Chemistry
|August 28, 2004
PubMed

Insights

Suppressing the c-Jun N-terminal kinase (JNK) pathway in the liver improves insulin resistance and glucose tolerance in diabetic mice. This targeted approach offers a promising strategy for managing diabetes by reducing hepatic glucose production.

Area of Science:

  • Metabolism and Endocrinology
  • Molecular Biology

Background:

  • The c-Jun N-terminal kinase (JNK) pathway is implicated in diabetic conditions and insulin resistance progression.
  • Understanding JNK pathway's role in liver is crucial for metabolic disease management.

Purpose of the Study:

  • To investigate the impact of modulating the JNK pathway in the liver on insulin resistance and glucose tolerance.
  • To assess the therapeutic potential of JNK pathway suppression in diabetes models.

Main Methods:

  • Overexpression of dominant-negative and wild-type JNK in mouse liver models.
  • Analysis of insulin signaling pathway components and gluconeogenic enzyme expression.
  • Evaluation of glucose tolerance and insulin sensitivity.

Main Results:

  • Dominant-negative JNK overexpression significantly improved insulin resistance and lowered blood glucose in obese diabetic mice.
  • Wild-type JNK expression impaired insulin sensitivity in normal mice.
  • JNK pathway suppression reduced key gluconeogenic enzyme expression and hepatic glucose production.
  • Beneficial effects were consistent across genetic and dietary diabetes models.

Conclusions:

  • Suppression of the JNK pathway in the liver demonstrates significant therapeutic benefits for insulin resistance and glucose intolerance.
  • Targeting the hepatic JNK pathway presents a viable strategy for treating both genetic and diet-induced diabetes.

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.